IMMUNOS THERAPEUTICS

ImmunOs Therapeutics AG has developed a proprietary human leukocyte antigen (HLA)-based platform to generate a novel class of biologic therapeutics for the treatment of cancer and autoimmune disease... ImmunOs is backed by an international consortium of top-tier investors, including Samsara Biocapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Mission BioCapital, and BioMed Partners... ImmunOs has established a comprehensive data set of validated results with a global team of scientific and commercial immunotherapy, immunology, and oncology experts. In preclinical studies, therapeutic efficacy of the Company's lead program, IOS-1002, has been demonstrated as monotherapy and in combination with standard-of-care cancer therapies.

Also known as: ImmunOs Therapeutics AG, The ImmunOs Therapeutics AG

VAT numbers: CHE-456.329.046

Primary location: Schlieren Switzerland